 CAMBRIDGE, Mass.--BUSINESS WIRE--Epizyme, Nasdaq: EPZM, a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial 877 844-6886 domestic or 970 3 